BOXMEER, The Netherlands and LONDON, September 26 /PRNewswire/ -- Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, and Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announced that Nobilon has licensed Protherics' CoVaccine HT(TM) adjuvant for use in pandemic influenza vaccines, and seasonal influenza vaccines in elderly people.
More than 300 million doses of seasonal influenza vaccine are produced each year globally, leaving a considerable shortfall in the event of a pandemic influenza outbreak. A powerful adjuvant, such as CoVaccine(TM), may reduce the amount of antigen required in a pandemic influenza vaccine, enabling rapid, large scale production in the event of a pandemic influenza outbreak and for planned stockpiling. In addition, the CoVaccine HT(TM) adjuvant may increase the potency of a seasonal influenza vaccine for elderly people, with impaired immune systems.
The licensing agreement gives Nobilon the exclusive, global rights excluding the US, to develop, manufacture and commercialize two new influenza vaccines containing CoVaccine HT(TM). Protherics will receive an upfront payment from Nobilon on signing the agreement. Protherics is also entitled to receive success related milestone payments and royalty payments on net sales by Nobilon.
Also announced today, Nobilon and a consortium of leading European vaccine experts has received a EUR3.5 million grant to help fund the development of a pandemic influenza vaccine containing CoVaccine HT(TM).
Han van den Bosch, director Research and Development of Nobilon
commented: "We are delighted to have gained exclusive access to CoVaccine
HT, a promising new adjuvant from Protherics, for use in our flu vaccines.
The very encouraging results in preclinical experiments using Nobilon's
influenza antigen produced by cell culture and Protherics' CoVaccine
adjuvant, justifies further clini
|SOURCE N.V. Organon|
Copyright©2007 PR Newswire.
All rights reserved